Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

Fjarde AP Fonden Fourth Swedish National Pension Fund cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 48.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,388 shares of the medical equipment provider’s stock after selling 41,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Hologic were worth $3,128,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of HOLX. General Partner Inc. purchased a new stake in shares of Hologic during the fourth quarter valued at $26,000. Groupama Asset Managment boosted its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. UBS Group raised their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Finally, Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Down 1.3 %

Shares of HOLX opened at $64.36 on Thursday. The business’s 50 day moving average is $69.48 and its 200 day moving average is $76.19. The company has a market capitalization of $14.44 billion, a PE ratio of 20.30, a price-to-earnings-growth ratio of 2.14 and a beta of 0.98. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.